Trulicity is the brand name for dulaglutide, a once-weekly injectable medication that belongs to the GLP-1 receptor agonist class and is FDA-approved to improve blood sugar in adults and some children with type 2 diabetes. It may also lower the risk of major cardiovascular events in people with type 2 diabetes who have established heart disease or multiple risk factors.
How Trulicity Works in the Body
Trulicity mimics a natural gut hormone called glucagon-like peptide-1 (GLP-1). When you eat, your small intestine releases GLP-1, which signals the pancreas to release insulin, slows the stomach from emptying too quickly, and tells the brain you are full. In type 2 diabetes, this GLP-1 response is often blunted.
Dulaglutide is engineered to resist rapid breakdown, so a single weekly dose keeps GLP-1 signaling active for seven days. This steady stimulation tends to lower both fasting and post-meal glucose without causing the frequent lows seen with insulin or sulfonylureas. Because food moves through the stomach more slowly, many people also report feeling satisfied with smaller portions, which is why modest weight loss is a common secondary effect.
Who Trulicity Is Prescribed For
The FDA has approved Trulicity as an add-on to diet and exercise for adults with type 2 diabetes. In 2022, the label was extended to include children aged 10 and older with type 2 diabetes who have not achieved target A1C on metformin. It is also approved to reduce major adverse cardiovascular events in adults with type 2 diabetes who have established heart disease or multiple cardiovascular risk factors.
Trulicity is not indicated for type 1 diabetes, diabetic ketoacidosis, or prediabetes. If you are in the prediabetes range, evidence-based first steps typically include structured lifestyle change, weight management, and sometimes metformin — not GLP-1 injections.
Trulicity Dosing Schedule
Trulicity is supplied in single-dose prefilled pens. According to the manufacturer’s prescribing information, the typical titration schedule is:
| Step | Dose | Duration | Purpose |
|---|---|---|---|
| Starting dose | 0.75 mg weekly | At least 4 weeks | Initial A1C control, minimize nausea |
| Standard increase | 1.5 mg weekly | At least 4 weeks before next step | Most common maintenance dose |
| Higher dose | 3.0 mg weekly | At least 4 weeks | Additional A1C reduction if needed |
| Maximum dose | 4.5 mg weekly | Ongoing | Maximum approved dose for A1C control |
Injections can be placed in the abdomen, thigh, or upper arm and should be rotated weekly. The pen is designed so the needle is hidden until it activates, which many users find less intimidating than traditional insulin pens.
Expected A1C and Weight Effects
In the AWARD clinical trial program, dulaglutide reduced A1C by roughly 0.7 to 1.5 percentage points depending on dose and background therapy. Weight reduction in the same trials averaged 2 to 5 kg (about 4 to 11 pounds) over six to twelve months, with the 4.5 mg dose producing the largest effects. Individual results vary considerably, and some people experience little change while others respond strongly.
If your goal is to better understand what your numbers mean before or during therapy, the A1C levels hub explains normal, prediabetes, and diabetes ranges.
Common Side Effects
Gastrointestinal side effects are the most frequently reported issues, typically most noticeable during the first few weeks or after a dose increase. They usually ease as the body adapts.
- Nausea (12 to 21 percent of users in trials)
- Diarrhea (9 to 13 percent)
- Vomiting (6 to 13 percent)
- Abdominal pain or bloating
- Decreased appetite
- Fatigue during dose titration
- Injection site reactions (usually mild)
Drinking water, eating smaller meals, avoiding greasy foods, and stopping meals at the first sign of fullness may help manage nausea.
Serious Warnings and Boxed Safety Information
Trulicity carries a boxed FDA warning about the risk of thyroid C-cell tumors observed in rodent studies. It should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Other serious but less common risks include pancreatitis, gallbladder disease, acute kidney injury (usually linked to dehydration from vomiting or diarrhea), severe gastrointestinal reactions, and diabetic retinopathy complications in people with pre-existing eye disease. Severe low blood sugar can occur when Trulicity is combined with insulin or sulfonylureas.
Seek medical attention for persistent severe abdominal pain, signs of an allergic reaction, or symptoms of dehydration.
Drug Interactions and Special Populations
Because Trulicity slows gastric emptying, it may alter how quickly oral medications are absorbed. Most interactions are clinically minor, but people on narrow-therapeutic-index drugs should discuss timing with their pharmacist.
Trulicity has not been well-studied in pregnancy and is generally discontinued at least two months before a planned pregnancy, per the prescribing information. Dose adjustment is not required for kidney or liver impairment, but hydration monitoring is important when kidney function is reduced.
How Trulicity Compares With Other GLP-1 Medications
Several once-weekly and daily GLP-1 products are now available. The table below summarizes differences based on current FDA labels.
| Medication | Active Ingredient | Frequency | Approved For |
|---|---|---|---|
| Trulicity | Dulaglutide | Once weekly | Type 2 diabetes, CV risk reduction |
| Ozempic | Semaglutide | Once weekly | Type 2 diabetes, CV risk reduction |
| Wegovy | Semaglutide (higher dose) | Once weekly | Chronic weight management |
| Victoza | Liraglutide | Once daily | Type 2 diabetes |
| Mounjaro | Tirzepatide (GLP-1 + GIP) | Once weekly | Type 2 diabetes |
Choice between agents depends on cost, insurance coverage, tolerability, cardiovascular benefit data, and personal preference about injection devices.
Cost, Insurance, and Savings Programs
Trulicity’s list price is high, but most people with commercial insurance pay less through copay cards offered by the manufacturer. Medicare and Medicaid coverage varies by plan. If cost is a barrier, ask your prescriber about patient assistance programs, therapeutic alternatives, or whether an older drug like metformin is appropriate. Lifestyle programs that align with the diet and nutrition fundamentals remain foundational no matter what medication you take.
Practical Tips for Starting Trulicity
- Pick a consistent injection day so refills and dose increases stay on track.
- Store pens in the refrigerator; one pen may be kept at room temperature for up to 14 days if needed.
- Rotate injection sites weekly to avoid lumps or skin changes.
- Eat smaller, lower-fat meals during the first month to reduce nausea.
- Keep a glucose meter handy, especially if you also take insulin or a sulfonylurea.
- Tell all providers (including dentists and surgeons) that you take a GLP-1 agonist.
The Bottom Line
Trulicity (dulaglutide) is a once-weekly GLP-1 injection that may meaningfully lower A1C, support modest weight loss, and reduce cardiovascular risk in adults with type 2 diabetes. It is not a cure, not a first-line option for prediabetes, and carries real risks that deserve a thorough conversation with your prescriber. Used alongside nutrition changes, physical activity, and regular monitoring, it can be a valuable tool — but the right choice depends on your full medical history, goals, and budget.
